塞来昔布治疗膝关节骨性关节炎的临床观察

The clinical observation of Celecoxib in treatment of OA

目的:探讨塞来昔布应用于膝关节骨性关节炎(OA)的疗效及安全性。方法:选择2005年1月～2008年6月在我院治疗的OA患者150例,随机分为塞来昔布组(治疗组)及布洛芬组(对照组),每组75例。治疗组予口服塞来昔布100mg,每日2次。对照组予口服布洛芬200mg,每日3次。两组均服用4周后观察疗效。结果:治疗组总有效率为90.67%,对照组总有效率为81.33%,治疗组疗效优于对照组(P<0.05)。患者的视觉模拟评分(VAS)显示,治疗组疼痛缓解情况明显优于对照组(P<0.05)。治疗组发生不良反应4例(5.33%),对照组发生不良反应共12例(16.00%),治疗组不良反应发生率低于对照组(P<0.05)。结论:塞来昔布治疗OA疗效可靠,不良反应少,适宜临床使用。

Objective： To investigate the efficacy and safety of Celecoxib in treatment of OA. Methods： Select from January 2005 to June 2008 in our hospital, 150 cases of OA patients were randomly divided into Celecoxib group （treatment group）and Ibuprofen group（control group）, 75 cases of each group. To the oral treatment group, Celecoxib 100 mg,twice daily. Control group of oral Ibuprofen to 200 mg,three times a day. Both groups were observed after four weeks to take effect. Results： The total effective rate in the treatment group was 90.67% ,the control group was 81.33%, and the treatment group was better than control group（P〈0.05）. Patients VAS showed that pain relief treatment group was obviously better than the control group （P〈0.05）. The adverse reaction in the treatment group and control group were 4 cases （5.33%）and 12 cases（16.00%）, the adverse reaction rate of the treatment group was lower than the control group （P〈0.05）. Conclusion： Celecoxib in treatment of OA has reliable effect,less adverse reactions,and suitable for clinical